Overview

Pharmacological vs Surgical Treatment for Mixed Incontinence

Status:
Unknown status
Trial end date:
2010-01-01
Target enrollment:
0
Participant gender:
Female
Summary
In patients with symptoms of mixed incontinence (loss of urine associated with coughing/sneezing/laughing, and loss of urine associated with the strong urge to void), is surgical treatment with tension free vaginal tape or pharmacological treatment with tolterodine more effective? What are the parameters predictive of success or failure with either forms of treatment? What are the parameters predictive of the necessity for further treatment after primary treatment? Patients will be randomised to having surgical or pharmacological treatment for their mixed incontinence symptoms. They will be assessed subjectively and objectively pre-treatment and after treatment at intervals up to 3 months.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Imperial College London
Treatments:
Tolterodine Tartrate
Criteria
Inclusion Criteria:

1. Patients must be female as this is a urogynaecology study.

2. An age of between 35 and 70 years. This takes into account that incontinence tends to
prevail in women with advancing years. Younger women may be planning to start a family
which precludes them from participating.

3. Clinical urodynamic evidence of mixed incontinence with prevalence of symptoms of
stress incontinence assessed by means of a specific questionnaire and visual analog
scale (VAS). The study is assessing the treatment of mixed incontinence and the
patients will have to have evidence of this which is provided by their symptoms.

4. Candidates for corrective surgery of the component of sphincter defect with Ba < - 1
according to the International Continence Society (ICS) classification of genital
prolapse.

5. Patients capable of filling in the micturition diary, the VAS, and the pathology
specific quality of life questionnaire, the Kings Health Questionnaire. These form
part of the continuing assessment of effectiveness of treatment.

6. Patients capable of understanding and signing an informed written consent form for
participating in the trial. If patients are unable to give their consent for the
procedures and investigations they cannot be ethically recruited.

7. Patients who accept not to give birth vaginally in the future, so as not to jeopardize
the results of the surgical operation.

Exclusion Criteria:

1. Contraindications for using anti-cholinergic agents (urinary retention, uncontrolled
narrow-angle glaucoma, myasthenia gravis, severe ulcerative colitis, toxic megacolon).
Anticholinergics form one group of the patients and inability to take these drugs
therefore precludes them from participating.

2. Ascertained hypersensitivity to tolterodine or any of the excipients. For the above
reason.

3. Presence of pathologies or conditions that in the Investigator's opinion make the
patient unsuitable for inclusion.

4. Patients with urinary tract infections (UTI) during the run-in period.

5. Patients with recurrent urinary tract infections (> 5 in the past 12 months).

6. Patients with diagnosed interstitial cystitis.

These compromise the results obtained.

7. Patients with haematuria of uncertain origin. These patients need urgent investigation
of these signs with procedures that are not included in the study.

8. Patients on treatment with anti-cholinergic agents of other drugs acting on detrusor
instability. This will compromise the results of the study if for example these
patients are randomised into the surgical group.

9. Patients on treatment with oestrogens, unless the therapy was commenced at least 2
months prior to inclusion in the study and follows a constant dosage.

10. Patients on diuretics. This affect their urinary behaviour.

11. Patients on concomitant treatment with potent CYP 34A inhibitors, such as macrolide
antibiotics or antimycotic agents.

12. Patients who have undergone previous surgery on the distal urinary tract (with the
exception of hysterectomy).

13. Patients who do not have adequate contraceptive cover or patients who are
breast-feeding. For reasons of avoiding pregnancy during the study.